Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3371468 | 1.00 | KDM4E (0.34) | KDM4EHTTALDH1A1HPGDAAK1 | |
| SCHEMBL3373060 | 0.88 | MAPT (0.35) | KDM4EHTTALDH1A1HPGDMEN1 | |
| SCHEMBL13069298 | 0.85 | AAK1 (0.34) | KDM4EHTTALDH1A1HPGDAAK1 | |
| SCHEMBL5570142 | 0.81 | METAP1 (0.36) | KDM4EHTTALDH1A1HPGDMEN1 | |
| SCHEMBL5570139 | 0.81 | METAP1 (0.36) | KDM4EHTTALDH1A1HPGDMEN1 | |
| SCHEMBL3372661 | 0.79 | MAPT (0.44) | KDM4EHTTALDH1A1HPGDMEN1 | |
| SCHEMBL3370325 | 0.76 | ALDH1A1 (0.34) | ALDH1A1HPGDMEN1MAPTKMT2A | |
| SCHEMBL3370330 | 0.76 | ALDH1A1 (0.34) | ALDH1A1HPGDMEN1MAPTKMT2A | |
| SCHEMBL3375285 | 0.76 | ALDH1A1 (0.36) | KDM4EALDH1A1HPGDMEN1MAPT | |
| SCHEMBL3374050 | 0.76 | ALDH1A1 (0.36) | KDM4EALDH1A1HPGDMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869036-B1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | claimed |
| EP-1869036-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | claimed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | claimed |
| WO-2006106046-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | claimed |
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | LIU JIN-JUN | 2006-10-05 | — | — | US | claimed |
| EP-1869036-B1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | disclosed |
| EP-1869036-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | disclosed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | disclosed |
| WO-2006106046-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | LIU JIN-JUN | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | CDK4, CDK1, CDK14 | KDM4E 672/4885HTT 3201/4885ALDH1A1 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.